Craig Slingluff
Vice Chair of Research · University of Virginia Medical Center
Credentials: · · ·
History
PresentResearch · University of Virginia Medical Center
- Present
Surgery · University of Virginia Medical Center
- 1984–1985
Research
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Cell · 2017 · 1,867 citations
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment
Cancer Research · 2009 · 941 citations
Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase
Science · 2002 · 811 citations
30 papers
27 papers · 11 as a resident
- WG
25 papers
23 papers
- KL
16 papers · 16 as a resident
14 papers · 14 as a resident
13 papers
13 papers · 12 as a resident
Grants
- 2011–2031
Postdoctoral Training Grant for MDs in Surgical Oncology Research
National Cancer Institute · T32
Contact PI · $4.6M · University of Virginia
- 1997–2027
University of Virginia Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $1.5M · University of Virginia
- 2017–2019
Antibodies to Melanoma Vaccine Peptides
National Cancer Institute · R03
Contact PI · $161.3K · University of Virginia
- 2013–2019
Melanoma Vaccine for Helper t Cells Combined with Targeted or Immune Therapies
National Cancer Institute · R01
Contact PI · $1.2M · University of Virginia
Clinical trials
- 2023–2028
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
Principal investigator · Recruiting
Craig L Slingluff, Jr
- 2020–2024
Principal investigator · Completed · Phase 1, Phase 2
Craig L Slingluff, Jr
- 2018–2024
Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma
Principal investigator · Completed · Phase 1, Phase 2
Craig L Slingluff, Jr
- 2015–2018
Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma
Principal investigator · Terminated · Phase 1, Phase 2
Craig L Slingluff, Jr